Agreed, they are moving past RIA.
The way I read it (and I have no where near the expertise of others here, granted), they have recognized that a colorimetric test will be necessary for commercialization. For the colorimetric test to be successful, they have "magnified the measured differences in serum values for RECAF between normal and cancer patients". This results in "detection of smaller tumors" and also fulfills a requirement for improved tests.
It sounds like much valuable and important work has been done that will allow for a colorimetric test, but I can't see anywhere that they state that a test is in hand... mostly they refer to it in the future tense.
But again, there's room for interpretation, which is frustrating. I called the company, but the IR person is out until Monday. I'll ask them if a colorimetric test in hand.